<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171104</url>
  </required_header>
  <id_info>
    <org_study_id>2013LS104</org_study_id>
    <nct_id>NCT02171104</nct_id>
  </id_info>
  <brief_title>MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis</brief_title>
  <official_title>MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-institution, phase II study is designed to test the ability to achieve donor&#xD;
      hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM)&#xD;
      using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug&#xD;
      monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe&#xD;
      osteopetrosis (OP).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects who achieve high-level donor hematopoietic engraftment</measure>
    <time_frame>Day +42 post-transplant</time_frame>
    <description>Defined as neutrophil recovery by Day +42 post-transplant and ≥ 80% donor cells on the myeloid fraction of peripheral blood at Day +100 post-transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of subjects who achieve high-level donor hematopoietic engraftment</measure>
    <time_frame>Day +100 post-transplant</time_frame>
    <description>Defined as ≥ 80% donor cells on the myeloid fraction of peripheral blood at Day +100 post-transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host disease</measure>
    <time_frame>Day +100 post-transplant</time_frame>
    <description>Incidence and severity of GvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>Day +100 post-transplant</time_frame>
    <description>Incidence of TRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regimen-related toxicity</measure>
    <time_frame>Day +100 post-transplant</time_frame>
    <description>Defined as infection, acute renal failure, respiratory failure, cardiac failure, and veno-occlusive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-HSCT changes in disease</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of radiographic, physiologic, neuro-psychologic, and/or biochemical aspects of the disease as assessed on a disease-specific basis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-HSCT changes in disease</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of radiographic, physiologic, neuro-psychologic, and/or biochemical aspects of the disease as assessed on a disease-specific basis</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mucopolysaccharidosis Disorders</condition>
  <condition>Hurler Syndrome</condition>
  <condition>Hunter Syndrome</condition>
  <condition>Maroteaux Lamy Syndrome</condition>
  <condition>Sly Syndrome</condition>
  <condition>Alpha-Mannosidosis</condition>
  <condition>Fucosidosis</condition>
  <condition>Aspartylglucosaminuria</condition>
  <condition>Glycoprotein Metabolic Disorders</condition>
  <condition>Sphingolipidoses</condition>
  <condition>Recessive Leukodystrophies</condition>
  <condition>Globoid Cell Leukodystrophy</condition>
  <condition>Metachromatic Leukodystrophy</condition>
  <condition>Niemann-Pick B</condition>
  <condition>Niemann-Pick C Subtype 2</condition>
  <condition>Sphingomyelin Deficiency</condition>
  <condition>Peroxisomal Disorders</condition>
  <condition>Adrenoleukodystrophy With Cerebral Involvement</condition>
  <condition>Zellweger Syndrome</condition>
  <condition>Neonatal Adrenoleukodystrophy</condition>
  <condition>Infantile Refsum Disease</condition>
  <condition>Acyl-CoA Oxidase Deficiency</condition>
  <condition>D-Bifunctional Enzyme Deficiency</condition>
  <condition>Multifunctional Enzyme Deficiency</condition>
  <condition>Alpha-methylacyl-CoA Racmase Deficiency</condition>
  <condition>Mitochondrial Neurogastrointestingal Encephalopathy</condition>
  <condition>Severe Osteopetrosis</condition>
  <condition>Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation)</condition>
  <condition>Inherited Metabolic Disorders</condition>
  <arm_group>
    <arm_group_label>IMD - Except Haplo-identical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inherited Metabolic Disease (IMD) - Except Haplo-Identical&#xD;
See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OP - Except Haplo-Identical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe Osteoperosis (OP) - Except Haplo-Identical&#xD;
See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OP and IMD -Haplo-Identical Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe Osteopetrosis (OP) and Inhterited Metabolic Disorders (IMD)&#xD;
-Haplo-Identical Only&#xD;
See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cALD SR-A (Standard-Risk, Regimen A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cALD SR-B (Standard-Risk, Regimen B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cALD HR-C (High-Risk, Regimen C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cALD HR-D (High-Risk, Regimen D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stem Cell Transplantation</intervention_name>
    <description>Infusion given on Day 0</description>
    <arm_group_label>IMD - Except Haplo-identical</arm_group_label>
    <arm_group_label>OP - Except Haplo-Identical</arm_group_label>
    <arm_group_label>OP and IMD -Haplo-Identical Only</arm_group_label>
    <arm_group_label>cALD HR-C (High-Risk, Regimen C)</arm_group_label>
    <arm_group_label>cALD HR-D (High-Risk, Regimen D)</arm_group_label>
    <arm_group_label>cALD SR-A (Standard-Risk, Regimen A)</arm_group_label>
    <arm_group_label>cALD SR-B (Standard-Risk, Regimen B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMD Preparative Regimen</intervention_name>
    <description>Anti-thymocyte Globulin (ATG)&#xD;
Fludarabine&#xD;
Busulfan</description>
    <arm_group_label>IMD - Except Haplo-identical</arm_group_label>
    <arm_group_label>cALD HR-C (High-Risk, Regimen C)</arm_group_label>
    <arm_group_label>cALD HR-D (High-Risk, Regimen D)</arm_group_label>
    <arm_group_label>cALD SR-A (Standard-Risk, Regimen A)</arm_group_label>
    <arm_group_label>cALD SR-B (Standard-Risk, Regimen B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osteopetrosis Only Preparative Regimen</intervention_name>
    <description>Anti-thymocyte Globulin (ATG)&#xD;
Fludarabine&#xD;
Busulfan&#xD;
Thiotepa</description>
    <arm_group_label>OP - Except Haplo-Identical</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osteopetrosis Haploidentical Only Preparative Regimen</intervention_name>
    <description>Rituximab&#xD;
Alemtuzumab&#xD;
Busulfan&#xD;
Fludarabine</description>
    <arm_group_label>OP and IMD -Haplo-Identical Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cALD SR-A (Standard-Risk, Regimen A)</intervention_name>
    <description>N-acetylcysteine start day +1 through day +28</description>
    <arm_group_label>cALD SR-A (Standard-Risk, Regimen A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cALD SR-B (Standard-Risk, Regimen B)</intervention_name>
    <description>N-acetylcysteine start day +1through day +56</description>
    <arm_group_label>cALD SR-B (Standard-Risk, Regimen B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cALD HR-D (High-Risk, Regimen C)</intervention_name>
    <description>N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100</description>
    <arm_group_label>cALD HR-C (High-Risk, Regimen C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cALD HR-D (High-Risk, Regimen D)</intervention_name>
    <description>N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100</description>
    <arm_group_label>cALD HR-D (High-Risk, Regimen D)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  0 through 55 years of age&#xD;
&#xD;
          -  Adequate graft available&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Eligible Diseases:&#xD;
&#xD;
               -  Mucopolysaccharidosis Disorders:&#xD;
&#xD;
                    -  MPS IH (Hurler syndrome)&#xD;
&#xD;
                    -  MPS II (Hunter syndrome) if the patient has no or minimal evidence of&#xD;
                       symptomatic neurologic disease but is expected to have a neurologic&#xD;
                       phenotype&#xD;
&#xD;
                    -  MPS VI (Maroteaux-Lamy syndrome)&#xD;
&#xD;
                    -  MPS VII (Sly syndrome)&#xD;
&#xD;
               -  Glycoprotein Metabolic Disorders:&#xD;
&#xD;
                    -  Alpha mannosidosis&#xD;
&#xD;
                    -  Fucosidosis&#xD;
&#xD;
                    -  Aspartylglucosaminuria&#xD;
&#xD;
               -  Sphingolipidoses and Recessive Leukodystrophies:&#xD;
&#xD;
                    -  Globoid cell leukodystrophy&#xD;
&#xD;
                    -  Metachromatic leukodystrophy&#xD;
&#xD;
                    -  Niemann-Pick B patients (sphingomyelin deficiency)&#xD;
&#xD;
                    -  Niemann-Pick C subtype 2&#xD;
&#xD;
               -  Peroxisomal Disorders:&#xD;
&#xD;
                    -  Adrenoleukodystrophy with cerebral involvement&#xD;
&#xD;
                    -  Zellweger syndrome&#xD;
&#xD;
                    -  Neonatal Adrenoleukodystrophy&#xD;
&#xD;
                    -  Infantile Refsum disease&#xD;
&#xD;
                    -  Acyl-CoA-Oxidase Deficiency&#xD;
&#xD;
                    -  D-Bifunctional enzyme deficiency&#xD;
&#xD;
                    -  Multifunctional enzyme deficiency&#xD;
&#xD;
                    -  Alpha-methylacyl-CoA Racmase Deficiency (AMACRD)&#xD;
&#xD;
                    -  Mitochondrial Neurogastrointestingal Encephalopathy (MNGIE)&#xD;
&#xD;
               -  Severe Osteopetrosis (OP)&#xD;
&#xD;
               -  Hereditary Leukoencephalopathy with axonal spheroids (HDLS; CSF1R mutation)&#xD;
&#xD;
               -  Other Inherited Metabolic Disorders (IMD): Patients will also be considered who&#xD;
                  have other life-threatening, rare lysosomal, peroxisomal or other similar&#xD;
                  inherited disorders characterized by white matter disease or other neurologic&#xD;
                  manifestations for which there is rationale that transplantation would be of&#xD;
                  benefit, such as certain patients with Wolman's disease, GM1 gangliosidosis,&#xD;
                  I-cell disease, Tay-Sachs disease, Sandhoff disease or others.&#xD;
&#xD;
               -  Voluntary written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy - menstruating females must have a negative serum or urine pregnancy test&#xD;
             within 14 days of study treatment start&#xD;
&#xD;
          -  Prior myeloablative chemotherapy exposure within 4 months of the start of conditioning&#xD;
             on this protocol (patients excluded for this reason may be eligible for other&#xD;
             institutional protocols)&#xD;
&#xD;
          -  Uncontrolled bacterial, fungal or viral infections including HIV (including active&#xD;
             infection with Aspergillus or other mold within 30 days)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Orchard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Burke</last_name>
    <phone>612-273-8482</phone>
    <email>lburke3@Fairview.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Troy Lund, M.D.Ph.D.</last_name>
    <phone>612-625-4185</phone>
    <email>lundx072@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Burke</last_name>
      <phone>612-273-8482</phone>
      <email>lburke3@Fairview.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allogeneic hematopoietic cell transplantation</keyword>
  <keyword>bone marrow transplantation</keyword>
  <keyword>IMD</keyword>
  <keyword>AMACRD</keyword>
  <keyword>MNGIE</keyword>
  <keyword>HDLS</keyword>
  <keyword>OP</keyword>
  <keyword>ALD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteopetrosis</mesh_term>
    <mesh_term>Zellweger Syndrome</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Adrenoleukodystrophy</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Leukoencephalopathies</mesh_term>
    <mesh_term>Leukodystrophy, Metachromatic</mesh_term>
    <mesh_term>Leukodystrophy, Globoid Cell</mesh_term>
    <mesh_term>Sphingolipidoses</mesh_term>
    <mesh_term>Fucosidosis</mesh_term>
    <mesh_term>Refsum Disease</mesh_term>
    <mesh_term>Refsum Disease, Infantile</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mannosidase Deficiency Diseases</mesh_term>
    <mesh_term>alpha-Mannosidosis</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
    <mesh_term>Mucopolysaccharidosis VII</mesh_term>
    <mesh_term>Peroxisomal Disorders</mesh_term>
    <mesh_term>Aspartylglucosaminuria</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

